Technical Analysis for GLTO - Galecto, Inc.

Grade Last Price % Change Price Change
D 5.77 10.01% 0.53
GLTO closed up 10.01 percent on Wednesday, June 16, 2021, on 20.38 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Up Up
Historical GLTO trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Fell Below 50 DMA Bearish 10.01%
Older End-of-Day Signals for GLTO ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 1 ATR about 6 hours ago
Possible Pocket Pivot about 7 hours ago
60 Minute Opening Range Breakout about 8 hours ago
1,2,3, Pullback Entry about 8 hours ago
Rose Above Previous Day's High about 8 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Galecto, Inc. Description

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of fibrosis related to non-alcoholic steatohepatitis, as well as development of other related indications, including cancer. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Clinical Medicine Biology Alcohol Inflammation Steatohepatitis Idiopathic Pulmonary Fibrosis Non Alcoholic Fatty Liver Disease Progressive Pulmonary Fibrosis Fibrosis Related Disease Related Diseases Breakthrough Therapy Copenhagen Fibrotic Disease Lectins mTOR Galectin Lung Diseases Myelofibrosis Treatment Of Fibrosis Galectin 3 Galecto Biotech

Is GLTO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 17.99
52 Week Low 4.54
Average Volume 1,071,258
200-Day Moving Average 0.00
50-Day Moving Average 5.48
20-Day Moving Average 5.22
10-Day Moving Average 5.47
Average True Range 1.11
ADX 46.34
+DI 63.70
-DI 5.08
Chandelier Exit (Long, 3 ATRs) 13.08
Chandelier Exit (Short, 3 ATRs) 7.87
Upper Bollinger Bands 6.62
Lower Bollinger Band 3.83
Percent B (%b) 0.7
BandWidth 53.39
MACD Line 0.07
MACD Signal Line -0.04
MACD Histogram 0.1155
Fundamentals Value
Market Cap 141.86 Million
Num Shares 24.6 Million
Price-to-Sales 0.00
Price-to-Book 11.08
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.81
Resistance 3 (R3) 7.83 7.16 7.47
Resistance 2 (R2) 7.16 6.64 7.16 7.36
Resistance 1 (R1) 6.47 6.32 6.82 6.45 7.24
Pivot Point 5.80 5.80 5.98 5.80 5.80
Support 1 (S1) 5.11 5.28 5.46 5.09 4.30
Support 2 (S2) 4.44 4.96 4.44 4.18
Support 3 (S3) 3.75 4.44 4.07
Support 4 (S4) 3.73